Dashboard
Manage Tickers

CGEM Cullinan Therapeutics, Inc.

Nasdaq cullinanoncology.com


$ 7.61 $ 0.16 (2.14 %)    

Monday, 10-Nov-2025 12:26:50 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 619.57 $ 0.82 (0.13 %)
DIA $ 471.24 $ -0.60 (-0.13 %)
SPY $ 677.81 $ 0.63 (0.09 %)
TLT $ 89.44 $ -0.04 (-0.05 %)
GLD $ 376.97 $ 1.03 (0.27 %)
$ 7.19
$ 7.49
$ 7.57 x 32
$ 7.61 x 10
$ 7.49 - $ 7.97
$ 5.68 - $ 17.50
712,027
na
424.76M
$ 0.76
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-17-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-10-2021 06-30-2021 10-Q
19 05-14-2021 03-31-2021 10-Q
20 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cullinan-therapeutics-q3-eps-077-beats-095-estimate
Cullinan Therapeutics Q3 EPS $(0.77) Beats...
11/06/2025 12:23:39

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of...

cullinan-therapeutics-to-present-new-clinical-data-from-phase-1-study-of-cln-049-investigational-flt3xcd3-bispecific-t-cell-engager-in-patients-with-rr-amland-mds-at-ahs-2025
Cullinan Therapeutics To Present New Clini...
11/03/2025 14:23:23

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patie...

reported-saturday-cullinan-therapeutics-presents-new-preclinical-data-showing-cln-978-drives-rapid-and-deep-b-cell-depletion-across-multiple-autoimmune-diseases
Reported Saturday, Cullinan Therapeutics P...
10/27/2025 06:53:15

cullinan-therapeutics-cancer-drug-shows-efficacy-in-brain-metastases-among-lung-cancer-patients-with-certain-mutations
Cullinan Therapeutics Cancer Drug Shows Ef...
10/13/2025 16:46:34

Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented at ...

reported-earlier-taiho-and-cullinan-report-phase-2b-results-for-zipalertinib-highlighting-688-intracranial-disease-control-and-favorable-safety-profile-at-esmo-2025
Reported Earlier, Taiho And Cullinan Repor...
10/13/2025 06:26:03

hc-wainwright--co-reiterates-buy-on-cullinan-therapeutics-maintains-24-price-target
HC Wainwright & Co. Reiterates Buy on Cull...
09/12/2025 10:37:32

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $24 pri...

taiho-oncology-and-cullinan-therapeutics-report-27-response-rate-in-rezilient1-and-30-response-rate-in-rezilient2-lung-cancer-trial
Taiho Oncology And Cullinan Therapeutics R...
09/09/2025 09:49:41

Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the REZILIENT1 and REZILIENT2 trials of zi...

hc-wainwright--co-assumes-cullinan-therapeutics-at-buy-announces-price-target-of-24
HC Wainwright & Co. Assumes Cullinan Thera...
08/21/2025 11:29:17

HC Wainwright & Co. analyst Robert Burns assumes Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Pri...

morgan-stanley-maintains-overweight-on-cullinan-therapeutics-lowers-price-target-to-28
Morgan Stanley Maintains Overweight on Cul...
08/18/2025 13:12:35

Morgan Stanley analyst Jeffrey Hung maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Overweight and lowers the price tar...

morgan-stanley-maintains-overweight-on-cullinan-therapeutics-lowers-price-target-to-28
Morgan Stanley Maintains Overweight on Cul...
08/18/2025 13:12:35

Morgan Stanley analyst Jeffrey Hung maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Overweight and lowers the price tar...

cullinan-therapeutics-q2-eps-107-misses-084-estimate
Cullinan Therapeutics Q2 EPS $(1.07) Misse...
08/07/2025 11:18:06

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate ...

taiho-oncology-and-cullinan-therapeutics-announces-presentation-of-new-data-from-zipalertinib-rezilient1-and-rezilient2-trials-at-iaslc-2025-world-conference
Taiho Oncology And Cullinan Therapeutics A...
07/22/2025 11:30:07

stifel-reinstates-buy-on-cullinan-therapeutics-announces-22-price-target
Stifel Reinstates Buy on Cullinan Therapeu...
06/11/2025 15:48:17

Stifel analyst Alex Thompson reinstates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and announces $22 price target.

cullinan-therapeutics-licenses-rights-to-velinotamig-fom-genrix-bio-for-development-in-autoimmune-diseases
Cullinan Therapeutics Licenses Rights To V...
06/04/2025 20:05:46

Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TC...

Core News & Articles
Reported Sunday, Taiho And Cullinan's Zipa...
06/02/2025 07:31:36

Highlights of the REZILIENT1 Phase 1/2 trial in the authors' conclusions include:Zipalertinib demonstrated clinically meani...

cullinan-therapeutics-and-taiho-to-present-phase-2b-results-from-rezilient1-trial-of-zipalertinib-in-previously-treated-egfr-ex20ins-nsclc-at-asco-2025
Cullinan Therapeutics And Taiho To Present...
05/22/2025 21:33:18

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positiv...

ubs-maintains-buy-on-cullinan-therapeutics-lowers-price-target-to-24
UBS Maintains Buy on Cullinan Therapeutics...
05/12/2025 20:10:02

UBS analyst David Dai maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and lowers the price target from $30 to $24.

cullinan-therapeutics-receives-ema-approval-for-cln-978-phase-1-study-in-active-difficult-to-treat-rheumatoid-arthritis-to-initiate-in-q2-2025
Cullinan Therapeutics Receives EMA Approva...
05/08/2025 11:07:12

Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumat...

cullinan-launches-study-for-treatment-aimed-at-sjgrens-patients
Cullinan Launches Study for Treatment Aime...
04/29/2025 11:09:20

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapi...

cullinan-to-present-results-from-rezilient1-phase-12-trial-of-zipalertinib-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-who-have-received-prior-therapy-at-asco-2025
Cullinan To Present Results from REZILIENT...
04/23/2025 14:16:31

CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company foc...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION